Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App





Randox Launches Mobile COVID-19 Lab that Processes 1000 Samples per Day and Generates Results in 1-3 Hours

By LabMedica International staff writers
Posted on 14 Dec 2020
Randox Laboratories (Crumlin, UK) has unveiled a new Mobile Laboratory Service which will offer rapid and reliable COVID-19 workplace testing.

The service from Randox, which is the largest COVID-19 testing provider in the UK and Ireland, and a partner in the UK Government’s National COVID-19 Testing Program, uses gold standard PCR technology to generate results in one-three hours. More...
Each Mobile Laboratory will be capable of processing up to 1,000 samples per day, to allow employers to uphold COVID safety within the workplace and maintain maximum output. As part of the Randox Mobile COVID-19 testing service, a team of healthcare professionals will collect the samples on site, and a Laboratory Technician will subsequently expedite the sample and reports the results.

The state-of-the-art Randox Mobile COVID-19 Laboratory comes fully staffed and stocked for testing, and is suitable for any and all industries. It can be booked to attend any location within the UK, providing a unique testing solution bespoke to each client’s needs.

“As the nation continues to navigate the working challenges caused by the COVID-19 pandemic, an increasing number of organizations will want to implement a COVID-19 testing regime so that they can sustain safe working environments,” said Dr. Peter FitzGerald, Randox Managing Director. “With this in mind we continue to expand our portfolio of bespoke testing products and services, and our latest addition, the Mobile Testing Laboratory, in conjunction with our work within the National Testing Programe, brings us one step closer to a timely return to a more normal society.”

“Since a new study by researchers at the University College London revealed that 86% of people who tested positive for COVID-19 did not have virus symptoms, frequent screening of asymptomatic patients, is vital to identify any hotspots and limit further spread,” added FitzGerald. “Our Mobile COVID-19 Laboratory, which uses gold standard PCR technology and can visit the location of your choice for immediate service, will promote safe working practices, allow companies to demonstrate their commitment to their staff, and facilitate recovery of the UK economy.”



Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gastrointestinal Panel
Xpert® GI Panel
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.